Effect of patiromer on urinary ion excretion in healthy adults

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 10, 2016, Pages 1769-1776

  Bushinsky, David A ^a   Spiegel, David M ^b   Gross, Coleman ^b   Benton, Wade W ^b   Fogli, Jeanene ^b   Hill Gallant, Kathleen M ^c   Du Mond, Charles ^b   Block, Geoffrey A ^d   Weir, Matthew R ^e   Pitt, Bertram ^f  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Relypsa Inc   (United States)

^c PURDUE UNIVERSITY   (United States)

^d Clinical Research at Colorado Kidney Care   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Animals; Brachyura; Calcium; Calcium, dietary; Cation exchange; Cations; Cross over studies; Diet; Electrolytes; Gastrointestinal absorption; Hyperkalemia; Intestinal absorption; Magnesium; Patiromer; Phosphates; Polymers; Potassium; Sodium; Urinary excretion

Indexed keywords

CALCIUM; MAGNESIUM; PATIROMER; PHOSPHATE; PLACEBO; POTASSIUM; SODIUM; ION; POLYMER;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD BIOCHEMISTRY; CALCIUM URINE LEVEL; CATION EXCHANGE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN EXPERIMENT; HYPERKALEMIA; MAGNESIUM URINE LEVEL; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHOSPHATE URINE LEVEL; POTASSIUM URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; SPECTROPHOTOMETRY; URINARY EXCRETION; URINE BIOCHEMISTRY; ADOLESCENT; CLINICAL TRIAL; CROSSOVER PROCEDURE; DIET; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; URINALYSIS; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; CALCIUM; CROSS-OVER STUDIES; DIET; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL ABSORPTION; HEALTHY VOLUNTEERS; HUMANS; IONS; MAGNESIUM; MALE; MIDDLE AGED; PHOSPHATES; POLYMERS; POTASSIUM; SODIUM; URINALYSIS; YOUNG ADULT;

EID: 84995898452     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01170216     Document Type: Article

References (25)

1. Li L, Harrison SD, Cope MJ, Park C, Lee L, Salaymeh F, Madsen D, Benton WW, Berman L, Buysse J: Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia [published online ahead of print February 7, 2016]. J Cardiovasc Pharmacol Ther
2. Sanofi-Aventis Canada, Inc.: Kayexalate (Sodium Polystyrene Sulfonate) Package Insert, Laval, Quebec, Canada, Sanofi-Aventis Canada, Inc., 2014
3. Xiao S: Division Memorandum: FDA Center for Drug Evaluation and Research. Medical Review for Application Number 205739Orig205731s205000, Silver Spring, MD, FDA Center for Drug Evaluation and Research, 2015
4. Agarwal R, Afzalpurkar R, Fordtran JS: Pathophysiology of potassium absorption and secretion by the human intestine. Gas-troenterology 107: 548–571, 1994
5. Fordtran JS, Locklear TW: Ionic constituents and osmolality of gastric and small-intestinal fluids after eating. Am J Dig Dis 11: 503–521, 1966
6. Wrong O, Metcalfe-Gibson A: The electrolyte content faeces. Proc R Soc Med 58: 1007–1009, 1965
7. Phillips SF, Giller J: The contribution of the colon to electrolyte and water conservation in man. J Lab Clin Med 81: 733–746, 1973
8. Buysse JM, Huang IZ, Pitt B: PEARL-HF: Prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016. Future Cardiol 8: 17–28, 2012
9. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36: 690–695, 1989
10. World Medical Association: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310: 2191–2194, 2013
11. ICH: ICH Harmonised Tripartite Guideline: Guideline for good clinical practice E6. Presented at the International Conference on Harmonisation, Geneva, Switzerland, 1996
12. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators: Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AME-THYST-DN Randomized Clinical Trial. JAMA 314: 151–161, 2015
13. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B: Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial. JAMA 312: 2223–2233, 2014
14. Relypsa: Veltassa (Patiromer Sorbitex Calcium) Package Insert, Redwood City, CA, Relypsa, 2015
15. Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS: Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest 83: 66–73, 1989
16. Bronner F, Pansu D: Nutritional aspects of calcium absorption. J Nutr 129: 9–12, 1999
17. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96: 53–58, 2011
18. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1–S201, 2003
19. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E: Mineral metabolism parameters throughout chronic kidney disease stages 1-5–achievement of K/DOQI target ranges. Nephrol Dial Transplant 22: 1171–1176, 2007
20. Daugirdas JT, Finn WF, Emmett M, Chertow GM; Frequent Hemodialysis Network Trial Group: The phosphate binder equivalent dose. Semin Dial 24: 41–49, 2011
21. Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P: Phosphate control in dialysis. Int J Nephrol Renovasc Dis 6: 193– 205, 2013
22. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators: Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372: 211–221, 2015
23. Quamme GA: Renal magnesium handling: New insights in understanding old problems. Kidney Int 52: 1180–1195, 1997
24. Ryan MP, Devane J, Ryan MF, Counihan TB: Effects of diuretics on the renal handling of magnesium. Drugs 28[Suppl 1]: 167–181, 1984
25. Gumz ML, Rabinowitz L, Wingo CS: An integrated view of potassium homeostasis. N Engl J Med 373: 60–72, 2015